查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1612743

癌症疼痛治疗市场：按药物类型、给药途径、应用和最终用途划分 - 全球预测 2025-2030

Cancer Pain Management Market by Drug Type (Nerve Blockers, Non-Opioids, Opioids), Route of Administration (Oral, Parental), Application, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症疼痛治疗市场价值为74.2亿美元，预计到2024年将达到78.6亿美元，复合年增长率为6.09%，预计到2030年将达到112.3亿美元。

癌症疼痛管理产业涵盖多种旨在缓解癌症患者疼痛的治疗方法和技术。此范围包括鸦片类药物、非类固醇消炎剂和辅助性治疗等药物治疗，以及针灸、物理治疗和神经调节等非药物治疗。癌症疼痛管理的需要源于伴随疾病及其治疗并影响患者生活品质的严重的、通常使人衰弱的疼痛。疼痛管理方案的应用超越了安宁疗护的范畴，并记录了患者在癌症治疗各阶段的生活品质和功能能力的提升。最终用途范围广泛，包括医院、门诊手术中心、专科诊所和居家照护机构。癌症发病率上升、疼痛管理技术的进步以及患者意识的提高和提高生活品质的需求对市场成长产生了重大影响。

主要市场统计
基准年[2023] 74.2亿美元
预测年份 [2024] 78.6亿美元
预测年份 [2030] 112.3亿美元
复合年增长率（%） 6.09%

关键的成长要素包括技术进步和开发更准确、更有效缓解疼痛的新疗法，以及有利的政府措施和对医疗基础设施的投资。新兴市场存在潜在的机会，这些市场获得有效疼痛管理的机会正在改善，综合疼痛管理方法的采用也在增加。抓住这些机会的研究包括投资创新研究以及扩大与医疗保健提供者的伙伴关係，以提供全面的疼痛管理解决方案。然而，该市场面临监管挑战、与先进治疗相关的高成本以及限制基于阿片类药物的管理策略的阿片类药物危机等限制。在低收入和中等收入国家提供个人化疼痛管理解决方案的进入障碍和复杂性也带来了挑战。

创新和研究应优先考虑整合个人化医疗、非鸦片类药物替代品和心理支持的整体方法。透过专注于这些细分市场，公司可以提高业务成长和市场差异化。市场的本质是动态的和多学科的，需要不断适应并将新的见解整合到综合癌症治疗策略中。癌症疼痛管理市场的相关人员可以透过适应不断变化的患者需求和法律规范，有效应对这一重要医疗保健领域的各种挑战和机会。

市场动态：揭示快速发展的癌痛管理市场的关键市场洞察

供需的动态交互作用正在改变癌症疼痛治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球慢性疼痛和文明病的盛行率不断上升
    • 老年人口的增加和对疼痛缓解治疗的需求
  • 市场限制因素
    • 产品召回问题
  • 市场机会
    • 持续的产品开发活动并增加了 FDA 的新产品核可
    • 政府资助支持癌症疼痛治疗
  • 市场问题
    • 与癌症疼痛治疗药物相关的副作用

波特五力：驾驭癌痛治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解癌症疼痛治疗市场的外在影响

外部宏观环境因素在塑造癌痛治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解癌症疼痛治疗市场的竞争格局

癌症疼痛管理市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：癌症疼痛管理市场供应商的绩效评估

FPNV 定位矩阵是评估癌痛管理市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製癌痛管理市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对癌痛治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地慢性疼痛和文明病的盛行率正在上升
      • 老年人数量不断增加，需要减轻疼痛的治疗方法
    • 抑制因素
      • 与产品召回相关的问题
    • 机会
      • 持续的产品开发活动和 FDA 对新产品的核准增加
      • 政府资助支持癌症疼痛治疗
    • 任务
      • 与癌症疼痛治疗药物相关的副作用
  • 市场区隔分析
    • 药物类型：扩大鸦片类药物治疗癌症疼痛的范围
    • 给药途径：口服药物越来越多地用于癌症疼痛治疗
    • 应用：乳癌癌痛管理解决方案的普及
    • 最终用途：医院中癌症镇痛药的使用增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章癌痛治疗市场：依药物类型

  • 介绍
  • 阻断剂
  • 非阿片类药物
    • 乙酰胺酚
    • 非类固醇消炎剂(NSAID)
  • 阿片类药物
    • Fentanyl
    • 氢可酮

第七章癌症疼痛治疗市场：依给药途径

  • 介绍
  • 口服
  • 母亲和孩子

第八章癌痛治疗市场：依应用分类

  • 介绍
  • 血癌
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第九章癌痛治疗市场：依最终用途分类

  • 介绍
  • 居家医疗
  • 医院
  • 专科诊所

第10章美洲癌痛治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区癌症疼痛治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的癌症疼痛治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准非鸦片类止痛药用于治疗轻度至中度疼痛
    • Nevro (NVRO) 最新发布客製化慢性疼痛治疗
    • 伊史蒂夫和美敦力合作满足癌症疼痛患者的需求
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Aegis Therapeutics, LLC
  • Aptinyx Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Grunenthal Group
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
Product Code: MRR-144C638C8F7B

The Cancer Pain Management Market was valued at USD 7.42 billion in 2023, expected to reach USD 7.86 billion in 2024, and is projected to grow at a CAGR of 6.09%, to USD 11.23 billion by 2030.

The Cancer Pain Management industry encompasses a wide range of treatments and technologies aimed at alleviating pain in individuals with cancer. This scope includes pharmacological treatments such as opioids, NSAIDs, and adjuvant therapies, along with non-pharmacological methods like acupuncture, physiotherapy, and neuromodulation. The necessity for cancer pain management arises from the severe, often debilitating pain that can accompany the disease and its treatments, impacting patients' quality of life. The application of pain management options extends beyond palliative care, offering enhanced life quality and functional capabilities for patients throughout various cancer treatment stages. End-use scopes are broad, including hospitals, ambulatory surgical centers, specialty clinics, and home care settings. Market growth is heavily influenced by the rising prevalence of cancer, advancements in pain management technologies, and increasing patient awareness and demand for quality of life improvements.

KEY MARKET STATISTICS
Base Year [2023] USD 7.42 billion
Estimated Year [2024] USD 7.86 billion
Forecast Year [2030] USD 11.23 billion
CAGR (%) 6.09%

Key growth factors include technological advancements and the development of new therapeutics aimed at more precise and effective pain relief, along with favorable government initiatives and investments in healthcare infrastructure. Potential opportunities lie in emerging markets where access to effective pain management is improving and the adoption of integrative pain management approaches is increasing. Recommendations to capture these opportunities involve investing in innovative research and expanding partnerships with healthcare providers for comprehensive pain management solutions. However, the market faces limitations including regulatory challenges, high costs associated with advanced therapies, and the opioid crisis, which limits opioid-based management strategies. Challenges also stem from barriers to access in low and middle-income countries and the complexity of achieving personalized pain management solutions.

Innovation and research should prioritize personalized medicine, non-opioid alternatives, and holistic approaches integrating psychological support. By focusing on these areas, companies can enhance business growth and market differentiation. The nature of the market is dynamic and multidisciplinary, requiring continuous adaptation and integration of novel insights into comprehensive cancer care strategies. By aligning with evolving patient needs and regulatory frameworks, stakeholders in the cancer pain management market can effectively address the diverse challenges and opportunities within this critical healthcare segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Pain Management Market

The Cancer Pain Management Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic pain and lifestyle disorders worldwide
    • Increasing geriatric population and need for pain-reducing therapies
  • Market Restraints
    • Issues associated with product recalls
  • Market Opportunities
    • Ongoing product development activities and rising FDA approvals of new products
    • Government funding supporting cancer pain treatments
  • Market Challenges
    • Adverse effects associated with cancer pain management drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Pain Management Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Pain Management Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Pain Management Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Pain Management Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Pain Management Market

A detailed market share analysis in the Cancer Pain Management Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Pain Management Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Pain Management Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Pain Management Market

A strategic analysis of the Cancer Pain Management Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Pain Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aegis Therapeutics, LLC, Aptinyx Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Glaxosmithkline PLC, Grunenthal Group, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Trevena Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Pain Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Nerve Blockers, Non-Opioids, and Opioids. The Non-Opioids is further studied across Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The Opioids is further studied across Fentanyl and Morphine.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End-Use, market is studied across Home care, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic pain and lifestyle disorders worldwide
      • 5.1.1.2. Increasing geriatric population and need for pain-reducing therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing product development activities and rising FDA approvals of new products
      • 5.1.3.2. Government funding supporting cancer pain treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with cancer pain management drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing applicability of opioids to treat cancer pain
    • 5.2.2. Route of Administration: Growing availability of oral medications for cancer pain management
    • 5.2.3. Application: Emerging penetration of cancer pain management solutions for breast cancer
    • 5.2.4. End-Use: Elevating usage of cancer pain drugs in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Pain Management Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Nerve Blockers
  • 6.3. Non-Opioids
    • 6.3.1. Acetaminophen
    • 6.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.4. Opioids
    • 6.4.1. Fentanyl
    • 6.4.2. Morphine

7. Cancer Pain Management Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Cancer Pain Management Market, by Application

  • 8.1. Introduction
  • 8.2. Blood Cancer
  • 8.3. Breast Cancer
  • 8.4. Colorectal Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer

9. Cancer Pain Management Market, by End-Use

  • 9.1. Introduction
  • 9.2. Home care
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Cancer Pain Management Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Pain Management Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Pain Management Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Non-Opioid Painkiller for Mild-to-Moderate Pain
    • 13.3.2. Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
    • 13.3.3. Esteve and Medtronic are Collaborating to Address Cancer Pain Patients' Needs
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Aegis Therapeutics, LLC
  • 4. Aptinyx Inc.
  • 5. Astellas Pharma Inc.
  • 6. Bausch Health Companies Inc.
  • 7. Baxter International Inc.
  • 8. Bayer AG
  • 9. Biogen Inc.
  • 10. Boehringer Ingelheim International GmbH
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. Glaxosmithkline PLC
  • 14. Grunenthal Group
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck & Co. Inc.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Regeneron Pharmaceuticals Inc.
  • 20. Sanofi SA
  • 21. Scilex Pharmaceuticals
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Trevena Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER PAIN MANAGEMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER PAIN MANAGEMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER PAIN MANAGEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER PAIN MANAGEMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NERVE BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 280. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 281. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023